Mumbai, February 1st, 2023
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter and nine months period ended 31st December, 2022.
Financial Highlights
- Net Sales for the quarter up 19% to Rs.1509 crores.
- Net Profit for the quarter at Rs. 122 crores.
- Net sales for 9M FY23 up 9% to Rs. 4246 crores.
- Net profit for 9M FY23 at Rs. 189 crores.
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The Company witnessed topline growth across all the verticals. In particular, the API business outperformed with a 65% growth during the quarter”
Operational Highlights
India Formulations Business
- India Formulations Business grew at 12% to Rs. 545 crores in the quarter reflecting performance better than the industry – both in Specialty and Acute segments
- Alembic’s specialty segment grew 14% compared to the industry specialty growth of 10% (as per IQVIA)
- Growth in specialty segment was driven by therapies like Gynecology, Anti-Diabetic & Ophthalmology.
- Alembic Acute business grew by 21% vs representative Industry growth of 11% (as per IQVIA).
International Business
- US Generics grew 10% to Rs. 432 crores in the quarter.
- Ex-US International Formulations grew 7% to Rs. 206 Crores in the quarter.
- 9 ANDA approvals received during the quarter; 178 Cumulative ANDA approvals.
- 4 ANDA filings during the quarter; Cumulative ANDA filings at 246.
API Business
- API business grew 65% at Rs. 326 crores in the quarter.
- 129 cumulative DMF Filings.
The summary of Total Revenue is as under:
(Rs in Crores)
| Particulars | Q3 FY23 | Q3 FY22 | % Change | 9M FY23 | 9M FY22 | % Change |
| Formulation | ||||||
| USA Ex- US | 432206 | 393193 | 10%7% | 1218602 | 1109587 | 10%3% |
| India | 545 | 488 | 12% | 1573 | 1478 | 6% |
| API | 326 | 198 | 65% | 853 | 716 | 19% |
| Total | 1509 | 1272 | 19% | 4246 | 3890 | 9% |
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a field force of over 4700 are well recognized by doctors and patients.
Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)
